Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.

CD74 interacts with APP and suppresses the production of Abeta.

Matsuda S., Matsuda Y., D'Adamio L.

BACKGROUND: Alzheimer disease (AD) is characterized by senile plaques, which are mainly composed of beta amyloid (Abeta) peptides. Abeta is cleaved off from amyloid precursor protein (APP) with consecutive proteolytic processing by beta-secretase and gamma-secretase. RESULTS: Here, we show that CD74, the invariant chain of class II major histocompatibility complex, interacts with APP and serves as a negative regulator of Abeta. CD74 resembles other APP interacters such as BRI2 and BRI3, since all of them reduce the level of Abeta. However, unlike BRIs, CD74 does not reduce the secretion of sAPPalpha or sAPPbeta. Interestingly, in HeLa cells, over expression of CD74 steers APP, but not Notch, to large vacuoles created by CD74. CONCLUSION: Taken together, we propose that CD74 inhibits Abeta production by interacting with and derailing normal trafficking of APP.

Mol Neurodegener 4:41-41(2009) [PubMed] [Europe PMC]

We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.

Do not show this banner again
UniProt is an ELIXIR core data resource
Main funding by: National Institutes of Health